Connexin43 hemichannel block protects against the development of diabetic retinopathy signs in a mouse model of the disease
- 56 Downloads
Diabetic retinopathy (DR) is a vascular disease of the neuroretina characterised by hyperglycaemia and inflammation. Current DR therapies target late-stage vascular defects and there is evidence to suggest that they contribute to geographic atrophy and retinal ganglion cell death long term. Therefore, alternative treatments that target common upstream disease mechanisms are needed. Recent studies have shown that connexin43 hemichannel blockers can reduce inflammation and prevent vessel leak in brain and spinal cord lesions. The aim of this study was to evaluate the effectiveness of a connexin43 hemichannel blocker (Peptide5) in a mouse model of DR in which pro-inflammatory cytokines, IL-1β and TNF-α, were intravitreally injected into non-obese diabetic (NOD, hyperglycaemic) mice. Fundus and optical coherence tomography images were taken to evaluate vessel dilation and beading as well as retinal and vitreous hyper-reflective foci (HRF). Immunohistochemistry was performed to assess levels of astrogliosis, microgliosis and inflammasome activation. Results showed that Peptide5 injection lowered the incidence of vessel dilation and beading, decreased the severity of vitreous and retinal HRF, and reduced sub-retinal fluid accumulation compared to the vehicle group. Furthermore, Peptide5 led to reduced connexin43 and GFAP upregulation, inhibited microglial infiltration into the outer nuclear layer and prevented upregulation of inflammasome markers compared to vehicle. The present study provides evidence in support of Peptide5, and connexin43 hemichannel block in general, as a potential upstream approach for the treatment of DR.
Connexin43 is upregulated in a novel mouse model of diabetic retinopathy (DR).
Connexin43 hemichannel block inhibits inflammation and inflammasome activation.
Connexin43 hemichannel block prevents the development of clinical DR signs.
Connexin43 hemichannel block is a potential upstream approach for DR treatment.
KeywordsDiabetic retinopathy Mouse models Connexin43 Hemichannels Inflammation
O.O.M. was supported by a doctoral scholarship from the Buchanan Ocular Therapeutics Unit, University of Auckland, New Zealand.
The study was partially funded by a Lottery Health Research Grant, Department of Internal Affairs, and an Auckland Medical Research Foundation Grant , New Zealand. C.R.G. holds the W&B Hadden Chair in Ophthalmology.
- 4.Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd, Comparison of Age-related Macular Degeneration Treatments Trials Research G (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119(7):1388–1398CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, Martin AA, Hagstrom SA, Martin DF, Group CR (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121(1):150–161CrossRefPubMedGoogle Scholar
- 7.Nishijima K, Ng YS, Zhong LC, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT (2007) Vascular endothelial growth factor-a is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171(1):53–67CrossRefPubMedPubMedCentralGoogle Scholar
- 18.De Bock M, Culot M, Wang N, Bol M, Decrock E, De Vuyst E, da Costa A, Dauwe I, Vinken M, Simon AM, Rogiers V, De Ley G, Evans WH, Bultynck G, Dupont G, Cecchelli R, Leybaert L (2011) Connexin channels provide a target to manipulate brain endothelial calcium dynamics and blood-brain barrier permeability. J Cereb Blood Flow Metab 31(9):1942–1957CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Wang N, De Vuyst E, Ponsaerts R, Boengler K, Palacios-Prado N, Wauman J, Lai CP, De Bock M, Decrock E, Bol M, Vinken M, Rogiers V, Tavernier J, Evans WH, Naus CC, Bukauskas FF, Sipido KR, Heusch G, Schulz R, Bultynck G, Leybaert L (2013) Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol 108(1):309CrossRefPubMedGoogle Scholar
- 22.Galinsky R, Davidson J, Bennet L, Green C, Gunn A (2015) Connexin Hemichannel blockade improves survival of striatal neurons after perinatal cerebral Ischaemia. J Paediatr Child Health 51:60Google Scholar
- 29.Mugisho OO, Rupenthal ID, Squirrell DM, Bould SJ, Danesh-Meyer HV, Zhang J, Green CR, Acosta ML (2018) Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy. PLoS One 13(8):e0202156. https://doi.org/10.1371/journal.pone.0202156 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, Norbury CC, Quinn PG, Sandirasegarane L, Simpson IA, Group JDRC (2006) Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55(9):2401–2411CrossRefPubMedGoogle Scholar
- 33.Coscas G, Lupidi M, Coscas F (2017) OCT-A: guided treatment of diabetic retinopathy. Acta Ophthalmol 95(S259)Google Scholar
- 45.Chaurasia SS, Lim RR, Parikh BH, Wey YS, Tun BB, Wong TY, Luu CD, Agrawal R, Ghosh A, Mortellaro A, Rackoczy E, Mohan RR, Barathi VA (2018) The NLRP3 Inflammasome may contribute to pathologic neovascularization in the advanced stages of diabetic retinopathy. Sci Rep 8(1):2847CrossRefPubMedPubMedCentralGoogle Scholar